Article

marketwatch.com on 2017-04-26 23:32

Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected

Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall ...

Related news